# central nervous system FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/central-nervous-system

> No upcoming FDA catalysts in central nervous system; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for central nervous system?

No upcoming FDA catalysts in central nervous system; 2 past events are recorded. Press release filed with the SEC (EX-99): "NEW YORK, December 31, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer's disease agitation, and has granted the application Priority Review designation." [Calendar and source filings](https://sec-api.dev/indications/central-nervous-system)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-337644, https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm (retrieved 2026-11-12). Last confirmed 2026-02-23. Cite: https://sec-api.dev/indications/central-nervous-system#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 30, 2025 | [SYMBRAVO® (meloxicam-rizatriptan) FDA approval](https://sec-api.dev/pdufa/meloxicam-rizatriptan) | AXSM | central nervous system | completed, approved | "On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® for the acute treatment of migraine with or without aura in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm)) |
| December 31, 2025 | [AUVELITY (dextromethorphan-bupropion) NDA/BLA acceptance](https://sec-api.dev/pdufa/dextromethorphan-bupropion) | AXSM | central nervous system | completed | "NEW YORK, December 31, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheimer's disease agitation, and has granted the application Priority Review designation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000119312525337644/axsm-ex99_2.htm)) |

## Drugs

- [SYMBRAVO® (meloxicam-rizatriptan)](https://sec-api.dev/pdufa/meloxicam-rizatriptan) (AXSM)
- [AUVELITY (dextromethorphan-bupropion)](https://sec-api.dev/pdufa/dextromethorphan-bupropion) (AXSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/central-nervous-system.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "central nervous system FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/central-nervous-system

```bibtex
@misc{secapidev_indications_central_nervous_system_20261116,
  title        = {central nervous system FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/central-nervous-system}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_central_nervous_system_20261116","title":"central nervous system FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/central-nervous-system","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
